Teva Pharmaceutical Industries Ltd
TASE:TEVA
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IL |
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
121.3B ILS |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| ZA |
A
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
48.4B ZAR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
989.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.1B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
302.9B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
230.9B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.1B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154B USD |
Loading...
|
Market Distribution
| Min | -85 210% |
| 30th Percentile | -8.6% |
| Median | 1.8% |
| 70th Percentile | 7.2% |
| Max | 23 652.1% |
Other Profitability Ratios
Teva Pharmaceutical Industries Ltd
Glance View
Teva Pharmaceutical Industries Ltd., a titan in the global pharmaceutical landscape, has navigated the intricate world of pharmaceuticals with a blend of strategic vision and operational efficiency. Founded in 1901 and headquartered in Israel, Teva has become synonymous with the production of affordable generic medications, a key pillar of its business model. The company's narrative is one of adaptability and foresight, having positioned itself as a leader in the generic drug sector by leveraging economies of scale and a vast distribution network. By acquiring and integrating smaller pharmaceutical firms over the years, Teva has expanded its portfolio to include a vast array of treatments that address a broad spectrum of therapeutic areas. This strategic expansion has enabled the company to offer nearly the same efficacy as brand-name drugs at a fraction of the cost, thus capturing significant market share and delivering value to both patients and healthcare systems worldwide. Beyond its prowess in generics, Teva has carved a niche in the specialty medicines market, focusing on innovative therapies that address complex conditions such as multiple sclerosis, migraine, and movement disorders. This dual-track approach to growth allows Teva to balance the volume-driven nature of the generics market with the higher margins offered by specialty drugs. The synthesis of these two facets – comprehensive generic offerings and targeted specialty pharmaceuticals – underpins Teva's revenue streams. Through a combination of robust pipeline development, strategic partnerships, and a commitment to operational excellence, Teva navigates the challenges of a competitive industry marked by ever-evolving regulations and pricing pressures, striving to maintain its status as a reliable provider of healthcare solutions on a global scale.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Teva Pharmaceutical Industries Ltd is 8.2%, which is above its 3-year median of -5.1%.
Over the last 3 years, Teva Pharmaceutical Industries Ltd’s Net Margin has increased from -16.4% to 8.2%. During this period, it reached a low of -16.4% on Dec 31, 2022 and a high of 8.2% on Jan 1, 2026.